Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zionexa
Paris, Francedenosgroup.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
Zionexa developed and commercialized molecular imaging solutions and companion diagnostics to guide targeted therapies in oncology. Its lead product, Cerianna ([18F]-fluoroestradiol), received FDA clearance in May 2020 as a PET imaging agent to detect estrogen receptor-positive lesions for treatment selection in recurrent or metastatic breast cancer. The company was acquired by GE Healthcare in May 2021. At acquisition, it had about two dozen employees and aimed to expand access to its diagnostic technology across the US.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Molecular imaging agentsin-vivo biomarkers
- Industry
- Medical Imaging
Beyond the preview
Go deeper on Zionexa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zionexa.